Skip to main content

August 2016

Recruitment : Quality Process Specialist require in Icon CR

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support Clinical Development – from compound selection to Phase I - IV clinical studies
ICON enjoys a strong reputation for quality and is focused on staff development. We make it our mission to attract the most diverse and creative minds into the business and we continually strive to provide opportunities for our people to excel, grow and build a great career. We understand that our greatest asset is the skills and talents of our people and they are truly what set us apart.

Post: Quality Process Specialist I

Career as Junior Scientific Assistant at Staff Selection Commission

Applications are invited from eligible candidates with Nationality/Citizenship as indicated under Para-6 of this Notice, for the Selection Posts indicated in Para-4 of this Notice. Only those Applications successfully filled through the Website ssconline.nic.in/selectionposts and Print out of Online Application along with all the required documents received in the concerned SSC Regional Office within the specified time are accepted. Procedure for Online Submission of Application consists of two stages – (i) Registration Part & (ii) Application Part.

Post : Junior Scientific Assistant

Walk in interview for Quality control at Shilpa Medicare

Shilpa Medicare Ltd. SEZ-Formulation Unit, we are among the fastest growing oncology formulation pharmaceutical company, looking for dynamic young energetic, creative and talented mate candidates for formulation unit at Jadcherla near Hyderabad

Vacancy in Inventory Maintain at Tweet India Pharmaceuticals

Tweet India Pharmaceuticals Pvt. Ltd. is being headed by Mr. A. K. Arora, who is backed up by his more than 35 years practical and successful experiences of Pharmaceutical Industry and has given his precious and valuable guidance in formulating latest strategies which is followed by many Pharmaceutical Companies, and has been the milestone for the Pharmaceutical Industries.
Mr. Arora has created history in establishing many products which are essential and are in the interest of the mankind. His last assignment for the last 22 years as one of the partner with Talent India has given the new heights, and created history in the industry.

Chugai Pharmaceutical Co., Ltd announced that emicizumab  received orphan drug designation by the Ministry of Health, Labour and Welfare for the prevention and reduction of bleeding episodes in patients with congenital FVIIl deficiency (hemophilia A) who developed inhibitors to FVIII. Emicizumab is a humanized bispecific antibody for subcutaneous injection under development for hemophilia A.

Chugai Pharmaceutical Co., Ltd. announced that it obtained a supplemental approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) on August 26, 2016, for the anti-cancer agent, capecitabine (Xeloda tablets 300) for the indication of “adjuvant chemotherapy for rectal cancer.” In Japan, Xeloda is currently on the market and its approved indications are “inoperable or recurrent breast cancer,” “postoperative adjuvant chemotherapy for colon cancer,” “advanced or refractory colorectal cancer, which is not amenable to curative resection” and “gastric cancer.”

Claris Lifesciences and its subsidiaries has received an Abbreviated New Drug Application (ANDA) approval for Flumazenil Injection USP, 0.5mg/SmL and 1mg/10mL multiple dose vials, in the United States of America. The ANDA approval has come for the same plant where the FDA had recently completed their Prior Approval Inspection (PAI).

Walk in interview for B.Pharm/M.Pharm(08 Posts) at Indian Drugs & Pharmaceuticals Limited - Government of India

IDPL is the largest Central Pharma Public Sector Undertaking in India with plants at Rishikesh, Gurgaon & Hyderabad and two Subsidiary Units at Chennai and Muzaffarpur.
The vision of first Prime Minister of India, Late Pt. Jawahar Lal Nehru regarding Indian Drug Industry was that “the drug industry must be in the public sector….. I think an industry of the nature of the drug industry should not be in the private sector anyhow. There are for too much exploitation of the public in this industry”. With the vision of the then Prime Minister of India, IDPL was incorporated in April, 1961 (Company Registration No. 3418 of 1961-1962 with Registrar of Companies, Delhi and having its Registered and Corporate Office at Gurgaon) with main objectives of creating self-sufficiency in respect of essential life saving medicines, to free the country from dependence on imports and to provide medicines to the millions at affordable prices and not to make millions from the medicines. IDPL was basically conceived and established as a part of Healthcare Infrastructure and has played a pioneering infra-structural role in the growth of Indian Drug Industry base.

PREPARATION METHOD, PROPERTIES AND CROSSLINKING OF HYDROGEL: A REVIEW

{ DOWNLOAD AS PDF }

ABOUT AUTHOR
Komal Saini*
Department of Pharmaceutics, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh
komalsainiks@gmail.com

ABSTRACT
Hydrogels comprises of different classes class of materials that could absorb considerable amount of water while maintaining their integrity in water having three dimensional, hydrophilic, polymeric networks. In the last few years, radical methods of preparation of hydrophilic polymers and hydrogels have evolved that may be used in the future in drug delivery applications. For successful and desirable applications, synthesis of new polymers and cross-linkers having more biocompatibility and better biodegradability would be beneficial. This review provides an overview of the different classes of hydrogels, their characterization, method of preparation, their advantages and disadvantages and cross-linking.

The anticancer agent Treakisym for Injection 100 mg (bendamustine hydrochloride, "Treakisym") has been approved in Japan for an additional indication of chronic lymphocytic leukaemia (CLL). Treakisym is the subject of a licensing agreement concluded between Eisai and SymBio Pharmaceuticals Limited.

Treakisym was initially approved in Japan in October 2010 for relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma. Under the licensing agreement concluded between the two companies, Eisai has been marketing the product in Japan since its launch in December 2010.

Symbio filed an application for this additional indication in December 2015 in response to a development request from the Japanese Ministry of Health, Labour and Welfare's Study Group on Unapproved and Off Label Drugs with high unmet medical needs. Chronic lymphocytic leukaemia is a blood cancer characterized by neoplastic transformation and excess propagation of lymphocytes, a type of white blood cell, in the bone marrow. With approximately 2,000 patients with chronic lymphocytic leukaemia in Japan as well as an incidence rate of new cases of approximately 0.3 in 100,000, this is a disease with high unmet medical need. Furthermore, Treakisym has been designated as an orphan drug for chronic lymphocytic leukaemia in Japan.

Eisai positions oncology as a key therapeutic area and is aiming to discovery revolutionary new medicines with the potential to cure cancer. Eisai remains committed to maximizing the value of Treakisym as well as its in-house developed anticancer agents including Halaven and Lenvima, seeking to contribute further to addressing the diverse needs of patients with cancer and their families.


Bendamustine hydrochloride is an anticancer agent originally synthesized by German (formerly 'East German') pharmaceutical company Jenapharm and is marketed in Europe under the brand names Ribomustin and Levact as a treatment for non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukaemia. In the United States the product has been approved by the US Food and Drug Administration and is currently marketed under the brand name Treanda for the treatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's lymphoma. Eisai concluded an exclusive licensing agreement with SymBio in August 2008 concerning the joint development and marketing of Treakisym in Japan, which was followed by a subsequent agreement between the two companies in May 2009 concerning the development and marketing of the agent in Singapore and South Korea.

<< Pharma News


Subscribe to PharmaTutor News Alerts by Email